{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Tablet+for+Oral+Suspension&page=2", "query": { "intervention": "Placebo Tablet for Oral Suspension", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 55, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Tablet+for+Oral+Suspension&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Tablet+for+Oral+Suspension&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T08:27:23.424Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02289482", "title": "A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "GSK2838232 PIB (SDD)", "type": "DRUG" }, { "name": "GSK2838232 PIB (API)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 20, "start_date": "2014-11-17", "completion_date": "2015-03-10", "has_results": false, "last_update_posted_date": "2017-05-15", "last_synced_at": "2026-10-09T08:27:23.424Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02289482" }, { "nct_id": "NCT01802918", "title": "Single Dose Escalation Study of GSK2838232 in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "GSK2838232", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 17, "start_date": "2013-02-18", "completion_date": "2013-11-21", "has_results": false, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-10-09T08:27:23.424Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01802918" }, { "nct_id": "NCT05579327", "title": "Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Monocarboxylate Transporter 8 Deficiency", "Allan-Herndon-Dudley Syndrome" ], "interventions": [ { "name": "Tiratricol", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rare Thyroid Therapeutics International AB", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "MALE", "summary": "4 Years and older · Male only" }, "enrollment_count": 20, "start_date": "2023-07-21", "completion_date": "2025-09-03", "has_results": false, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-10-09T08:27:23.424Z", "location_count": 6, "location_summary": "Kissimmee, Florida • Atlanta, Georgia • St Louis, Missouri + 3 more", "locations": [ { "city": "Kissimmee", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hillsborough", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05579327" }, { "nct_id": "NCT06833320", "title": "Propranolol Treatment for Postoperative Chylothorax", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Postoperative Chylothorax", "Congenital Heart Disease", "Open Heart Surgery", "Chylothorax" ], "interventions": [ { "name": "Propranolol Hydrochloride", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "June Wu", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Days", "maximum_age": "18 Years", "sex": "ALL", "summary": "7 Days to 18 Years" }, "enrollment_count": 50, "start_date": "2025-09-09", "completion_date": "2031-01-01", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-10-09T08:27:23.424Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06833320" }, { "nct_id": "NCT01597440", "title": "Long-term Outcome of N-Carbamylglutamate Treatment in Propionic Acidemia and Methylmalonic Acidemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Propionic Acidemia", "Methylmalonic Acidemia" ], "interventions": [ { "name": "N-carbamylglutamate", "type": "DRUG" }, { "name": "Standard of Care", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mendel Tuchman", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Hour", "maximum_age": "4 Weeks", "sex": "ALL", "summary": "1 Hour to 4 Weeks" }, "enrollment_count": 1, "start_date": "2012-09", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2017-04-26", "last_synced_at": "2026-10-09T08:27:23.424Z", "location_count": 7, "location_summary": "Los Angeles, California • Palo Alto, California • Aurora, Colorado + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01597440" }, { "nct_id": "NCT03224325", "title": "A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "TAK-831 Tablet T2", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "TAK-831 Suspension", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Neurocrine Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 50, "start_date": "2017-07-21", "completion_date": "2018-09-09", "has_results": true, "last_update_posted_date": "2021-06-14", "last_synced_at": "2026-10-09T08:27:23.424Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03224325" }, { "nct_id": "NCT07437105", "title": "Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VX-272", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Tezacaftor", "type": "DRUG" }, { "name": "Deutivacaftor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 160, "start_date": "2026-02-25", "completion_date": "2027-06-26", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-09T08:27:23.424Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07437105" }, { "nct_id": "NCT01818011", "title": "A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infections, Bacterial" ], "interventions": [ { "name": "GSK1322322 Initial fit for purpose tablets", "type": "DRUG" }, { "name": "GSK1322322 over granulated tablets", "type": "DRUG" }, { "name": "GSK1322322 intended commercial tablets", "type": "DRUG" }, { "name": "Placebo tablets", "type": "DRUG" }, { "name": "13C-GSK1322322 stable isotope powder", "type": "DRUG" }, { "name": "GSK1322322 for injection", "type": "DRUG" }, { "name": "Placebo injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 12, "start_date": "2013-08-07", "completion_date": "2013-10-18", "has_results": false, "last_update_posted_date": "2019-01-15", "last_synced_at": "2026-10-09T08:27:23.424Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01818011" }, { "nct_id": "NCT01713946", "title": "A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Tuberous Sclerosis Complex-associated Refractory Seizures" ], "interventions": [ { "name": "RAD001", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Antiepileptic drug (1 to 3 only)", "type": "DRUG" }, { "name": "open label RAD001 (only used for post-extension phase)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "2 Years to 65 Years" }, "enrollment_count": 366, "start_date": "2013-04-29", "completion_date": "2017-10-25", "has_results": true, "last_update_posted_date": "2018-11-07", "last_synced_at": "2026-10-09T08:27:23.424Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01713946" }, { "nct_id": "NCT04493671", "title": "Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pulmonary Disease", "Tuberculosis, Pulmonary", "Tuberculosis", "Multi Drug Resistant Tuberculosis", "Drug Sensitive Tuberculosis", "Drug-resistant Tuberculosis", "Mycobacterium Tuberculosis Infection" ], "interventions": [ { "name": "TBAJ-876 suspension", "type": "DRUG" }, { "name": "Placebo suspension", "type": "DRUG" }, { "name": "TBAJ-876 100 mg tablet", "type": "DRUG" }, { "name": "TBAJ-876 25 mg tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Global Alliance for TB Drug Development", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "19 Years to 50 Years" }, "enrollment_count": 137, "start_date": "2020-06-08", "completion_date": "2022-11-15", "has_results": false, "last_update_posted_date": "2025-06-04", "last_synced_at": "2026-10-09T08:27:23.424Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04493671" } ] }